Table 3.
Sensitivity and specificity of ctDNA-based screening tests in various cancer types.
| Test | # of Patients * | Cancer Type (Stage) | Sensitivity | Specificity | Citation |
|---|---|---|---|---|---|
| Epi proColon | 1544 | CRC | 68% | 80% | [118] |
| Epi proColon | 290 | CRC | 73.3% | 81.5% | [119] |
| Bluestar | 748 | PDAC | 51.9% | 100% | [120] |
| CancerSEEK ** | 9911 | Various | 27.1% | 98.9% | [121] |
| CancerSEEK | 1817 | Various (1–3) | 70% | >99% | [104] |
| Galleri | 944 | Various | 36–74% | 98% | [122] |
| Galleri | 1264 | Various | 54.9% | >99% | [95] |
| Galleri | 4077 | Various | 51.5% | >99% | [123] |
| OverC | 492 | Various | 72.4% | 99.2% | [124] |
| OverC | 639 | Various (1–3) | 80.6% | >99% | [125] |
| OverC | 360 | Various | 74.8% | 98.1% | [126] |
| OverC | 1010 | Various (1–3) | 68.5% | 96.3% | [127] |
* Total number of patients in the testing/validation set used to determine sensitivity and specificity. ** An earlier version of the CancerSEEK test was used in this clinical trial. Abbreviations: CRC: colorectal cancer; PDAC: pancreatic ductal adenocarcinoma.